LFMD

LifeMD Inc

Add to Watchlist

Advanced Chart

9.940

-0.47(-4.515%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.230

Open

10.140

VWAP

9.99

Vol

1.10M

Mkt Cap

451.75M

Low

9.805

Amount

11.01M

EV/EBITDA(TTM)

175.30

Total Shares

41.56M

459.08M

EV/OCF(TTM)

29.85

P/S(TTM)

1.90

LifeMD, Inc. is a direct-to-patient telehealth company that provides comprehensive virtual and in-home healthcare. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company operates through two segments: Telehealth and WorkSimpli. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. WorkSimpli is a provider of workplace and document services for consumers, gig workers, and small businesses. It operates brands including: PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild, a provider of digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

70.53M

+9.77%

67.76M

+26.91%

66.31M

+30.89%

Estimates Revision

The market is revising Upward the revenue expectations for LifeMD, Inc. (LFMD) for FY2025, with the revenue forecasts being adjusted by 0.34% over the past three months. During the same period, the stock price has changed by 33.60%.

Revenue Estimates for FY2025

Revise Upward

+0.34%

In Past 3 Month

Stock Price

Go Up

+33.60%

In Past 3 Month

5 Analyst Rating

46.88% Upside

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 14.60 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

46.88% Upside

Current: 9.940

Low

8.00

Averages

14.60

High

18.00

46.88% Upside

Current: 9.940

Low

8.00

Averages

14.60

High

18.00

Lake Street

Brooks O'Neil

Buy

maintain

$12 -> $18

2025-07-10

Reason

Lake Street

Brooks O'Neil

Price Target

$12 -> $18

2025-07-10

maintain

Buy

Reason

Lake Street analyst Brooks O'Neil raised the firm's price target on LifeMD to $18 from $12 and keeps a Buy rating on the shares. LifeMD is building a national, tech-enabled virtual care platform spanning primary care, weight management, men's and women's health, hormone therapy, and behavioral health, and with strong early traction, the company is scaling efficiently, the analyst tells investors in a research note.

BTIG

Buy

maintain

$12 -> $15

2025-05-29

Reason

BTIG

Price Target

$12 -> $15

2025-05-29

maintain

Buy

Reason

BTIG raised the firm's price target on LifeMD (LFMD) to $15 from $12 and keeps a Buy rating on the shares as part of a broader research note in summary of presentations at the recent Boston Digital Health Summit. The firm believe that nearly all companies in its coverage group can and will benefit from AI, though the direct-to-consumer solutions like LifeMD and Hims (HIMS) may be able to drive more value quickly given the relatively high number of engagements with members, especially with respect to obesity health, the analyst tells investors in a research note.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$12 → $14

2025-03-12

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$12 → $14

2025-03-12

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Sarah James

Buy

Reiterates

$15

2025-03-11

Reason

Cantor Fitzgerald

Sarah James

Price Target

$15

2025-03-11

Reiterates

Buy

Reason

Keybanc

Scott Schoenhaus

Buy

Maintains

$10 → $7

2025-01-08

Reason

Keybanc

Scott Schoenhaus

Price Target

$10 → $7

2025-01-08

Maintains

Buy

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD to $7 from $10 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of last year but saw a rebound in the last two months following the Trump election. In combination with consensus estimate cuts since the middle of last year, KeyBanc sees attractive buying opportunities in the space in 2025. From a valuation multiple perspective, the firm believes companies with healthy balance sheets and steady free cash flow profiles will see less risk to multiple contraction, even with more modest growth trends. Conversely, it sees the most risk for companies that have challenged balance sheets and limited profitability in the near and longer term.

Lake Street

Brooks O'Neil

Strong Buy

Initiates

$12

2024-12-10

Reason

Lake Street

Brooks O'Neil

Price Target

$12

2024-12-10

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD.O) is 166.94, compared to its 5-year average forward P/E of -5.30. For a more detailed relative valuation and DCF analysis to assess LifeMD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.30

Current PE

166.94

Overvalued PE

35.90

Undervalued PE

-46.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

5.14

Current EV/EBITDA

13.15

Overvalued EV/EBITDA

16.24

Undervalued EV/EBITDA

-5.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.37

Current PS

1.62

Overvalued PS

2.43

Undervalued PS

0.30

Financials

Annual

Quarterly

FY2025Q1

YoY :

+48.83%

65.70M

Total Revenue

FY2025Q1

YoY :

-141.21%

2.54M

Operating Profit

FY2025Q1

YoY :

-128.83%

1.92M

Net Income after Tax

FY2025Q1

YoY :

-105.26%

0.01

EPS - Diluted

FY2025Q1

YoY :

-93.32%

201.05K

Free Cash Flow

FY2025Q1

YoY :

-3.06%

86.84

Gross Profit Margin - %

FY2025Q1

YoY :

-71.22%

1.35

FCF Margin - %

FY2025Q1

YoY :

-119.39%

2.92

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.6M

USD

3-6

Months

746.9K

USD

6-9

Months

670.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

14.8K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.6M

USD

3-6

Months

746.9K

USD

6-9

Months

670.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

14.8K

USD

Months

LFMD News & Events

Events Timeline

2025-07-31 (ET)

2025-07-31

08:14:15

LifeMD names Webb Dray as Chief Operating Officer, promotes two execs

2025-06-10 (ET)

2025-06-10

15:32:34

Lilly taking 'aggressive stance' with virtual health partners, says Citi

2025-05-22 (ET)

2025-05-22

08:13:32

LifeMD collaborates with Novo Nordisk to launch $299 bundle for Wegovy

News

5.0

07-31Newsfilter

LifeMD Names COO and Promotes Two Executives

9.5

07-21Newsfilter

Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2025

8.0

07-07NASDAQ.COM

LifeMD Series A Cumulative Perpetual Preferred Stock Crosses Above 9.5% Yield Territory

People Also Watch

San Juan Basin Royalty Trust

Hawthorn Bancshares Inc

James River Group Holdings Ltd

Utah Medical Products Inc

54.950

USD

-1.17%

FAQ

What is LifeMD Inc (LFMD) stock price today?

The current price of LFMD is 9.94 USD — it has decreased -4.51 % in the last trading day.

LFMD

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LFMD News & Events

Events Timeline

News

People Also Watch

FAQ

What is LifeMD Inc (LFMD) stock price today?

What is LifeMD Inc (LFMD)'s business?

What is the price predicton of LFMD Stock?

What is LifeMD Inc (LFMD)'s revenue for the last quarter?

What is LifeMD Inc (LFMD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for LifeMD Inc (LFMD)'s fundamentals?

How many employees does LifeMD Inc (LFMD). have?

What is LifeMD Inc (LFMD) market cap?